Who are Radotinib HCl's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dasatinib Tablets, DW6012(Dasidiem tab. 10/100mg), imatinib (IM), Nilotinib 300 mg., Ponatinib + Blinatumomab, Nilotinib, Imatinib.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/radotinib-hcl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Radotinib HCl — Competitive Intelligence Brief

Radotinib HCl (Radotinib HCl) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: BCR-ABL tyrosine kinase inhibitor. Area: Oncology.

phase 3 BCR-ABL tyrosine kinase inhibitor BCR-ABL Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Radotinib HCl (Radotinib HCl) — Il-Yang Pharm. Co., Ltd.. Radotinib HCl is a BCR-ABL tyrosine kinase inhibitor designed to block the abnormal protein that causes chronic myeloid leukemia (CML).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Radotinib HCl TARGET	Radotinib HCl	Il-Yang Pharm. Co., Ltd.	phase 3	BCR-ABL tyrosine kinase inhibitor	BCR-ABL
Dasatinib Tablets	Dasatinib Tablets	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	BCR-ABL tyrosine kinase inhibitor	BCR-ABL, SRC family kinases
DW6012(Dasidiem tab. 10/100mg)	DW6012(Dasidiem tab. 10/100mg)	Dong Wha Pharmaceutical Co. Ltd.	marketed	Tyrosine kinase inhibitor combination	BCR-ABL, SRC family kinases
imatinib (IM)	imatinib (IM)	First Affiliated Hospital, Sun Yat-Sen University	marketed	Tyrosine kinase inhibitor	BCR-ABL, KIT, PDGFRA
Nilotinib 300 mg.	Nilotinib 300 mg.	King Abdullah International Medical Research Center	marketed	BCR-ABL tyrosine kinase inhibitor	BCR-ABL
Ponatinib + Blinatumomab	Ponatinib + Blinatumomab	Gruppo Italiano Malattie EMatologiche dell'Adulto	phase 3	Tyrosine kinase inhibitor, Bispecific monoclonal antibody	BCR-ABL1, CD19, CD3
Nilotinib, Imatinib	Nilotinib, Imatinib	Seoul St. Mary's Hospital	phase 3	Tyrosine kinase inhibitor (TKI)	BCR-ABL, KIT, PDGFRA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (BCR-ABL tyrosine kinase inhibitor class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Il-Yang Pharm. Co., Ltd. · 1 drug in this class
King Abdullah International Medical Research Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Radotinib HCl — Competitive Intelligence Brief. https://druglandscape.com/ci/radotinib-hcl. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab